ImmUniverse
PROJECT DURATION:
01/2020
—
TOTAL PROJECT DURATION:
5 Jahre
The Project
Immune-mediated inflammatory diseases (IMIDs) are increasing in industrialized countries worldwide. An in-depth understanding of common disease mechanisms through molecular profiling techniques is essential for future precision medicine strategies for IMIDs.
Our Role in the Project
HEALTH contributes with its core technologies – dermal OFM and metabolomics – to the international research of inflammatory-autoimmune diseases.
Research groups
Downloads
Customer/Funding Organization
Project Partner
Coordinator: Humanitas University, Italy
Project Lead: GlaxoSmithKline Research & Development Limited, UK
Project Details
ImmUniverse – Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
ImmUniverse is being performed by a European transdisciplinary consortium of 26 partners to pave the way towards a truly personalised understanding of two different IMIDs: Ulcerative Colitis and Atopic Dermatitis.
As a project partner, HEALTH supports the international consortium in identifying biomarker pattern and mechanistic principles with its two core technologies – dermal OFM and metabolomics. With these methods, the molecular fingerprint of the diseases is investigated in different tissues. These molecular data in combination with data on disease severity and progression from several clinical studies will lead to personalised therapy decisions.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853995. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Read more: www.immuniverse.eu
